Ells Anna L, Wesolosky Jason D, Ingram April D, Mitchell Patrick C, Platt Alexander S
Calgary Retina Consultants, Calgary, Alberta, Canada; University of Calgary, Faculty of Medicine, Calgary, Alberta, Canada.
Department of Ophthalmology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Can J Ophthalmol. 2017 Oct;52(5):468-474. doi: 10.1016/j.jcjo.2017.02.012. Epub 2017 Jul 19.
The aim of this study was to evaluate the visual and structural outcomes of eyes that received ranibizumab as treatment for retinopathy of prematurity (ROP).
This was a retrospective case series of infants who received a 0.2 mg (0.02 mL) intravitreal injection of ranibizumab as the primary treatment for type 1 ROP. Outcome measures included regression or recurrence of ROP, complications of treatment, and assessment of visual acuity and refractive error.
Forty-two eyes of 21 infants (13 male) were included. Mean gestational age and birth weight were 24.6 ± 1.3 weeks and 613 ± 91 g, respectively. Mean age at injection was 37.4 ± 2.2 weeks postmenstrual age, and mean follow-up period was 10.1 ± 7 months. Active neovascularization regressed rapidly, and anatomical outcomes were favourable in all eyes. Twelve eyes of 6 infants received supplemental laser photocoagulation at a mean post-menstrual age (PMA) of 72.0 ± 27.3 weeks when vascularization had not advanced beyond zone II. Visual acuity was measurable in 28 of 42 eyes. Mean visual acuity was 0.94 ± 0.36 logMAR. Mean spherical equivalent was +1.00. There were no ocular or systemic complications in these patients and no cicatricial complications were observed with no progression to stage 4 or 5 disease.
A single intravitreal dose of 0.2 mg (0.02 mL) ranibizumab showed favourable anatomical and functional outcomes in eyes with type 1 ROP.
本研究旨在评估接受雷珠单抗治疗早产儿视网膜病变（ROP）的眼部视觉和结构转归。
这是一项回顾性病例系列研究，纳入接受0.2 mg（0.02 mL）雷珠单抗玻璃体内注射作为1型ROP主要治疗的婴儿。观察指标包括ROP的消退或复发、治疗并发症以及视力和屈光不正评估。
纳入21例婴儿（13例男性）的42只眼。平均胎龄和出生体重分别为24.6±1.3周和613±91 g。平均注射年龄为孕龄37.4±2.2周，平均随访期为10.1±7个月。活动性新生血管迅速消退，所有眼的解剖学转归均良好。6例婴儿的12只眼在平均孕龄（PMA）72.0±27.3周时接受了补充激光光凝，此时血管化未进展至II区以外。42只眼中28只可测量视力。平均视力为0.94±0.36 logMAR。平均球镜等效度为+1.00。这些患者未出现眼部或全身并发症，未观察到瘢痕性并发症，且未进展至4期或5期疾病。
单次玻璃体内注射0.2 mg（0.02 mL）雷珠单抗在1型ROP眼中显示出良好的解剖学和功能转归。
